Correction to: Oncogenic RIT1 mutations in lung adenocarcinoma (Oncogene, (2014), 33, 35, (4418-4423), 10.1038/onc.2013.581);Oncogenic RIT1 mutations in lung adenocarcinoma

Oncogene

Volumn 33, Issue 35, 2014, Pages 4418-4423

  Berger, A H ^a,b   Imielinski, M ^a,b,c,d   Duke, F ^a   Wala, J ^a,b   Kaplan, N ^b   Shi, G X ^e   Andres, D A ^e   Meyerson, M ^a,b,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

cancer genetics; GTPase; lung adenocarcinoma; oncogene; RAS pathway; signal transduction

Indexed keywords

ERLOTINIB; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; SELUMETINIB; ANTINEOPLASTIC AGENT; ONCOPROTEIN; RAS PROTEIN; RIT1 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL TRANSFORMATION; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDEL MUTATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RIT1 GENE; SOMATIC MUTATION; 3T3 CELL LINE; ADENOCARCINOMA; ANIMAL; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PC12 CELL LINE; PROTEIN TERTIARY STRUCTURE; RAT; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UNITED STATES;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; PC12 CELLS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RATS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027931984     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-022-02300-2     Document Type: Erratum

References (43)

1. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-1120.
2. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012; 18: 349-351.
3. Janne PA, Meyerson M. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol 2012; 30: 878-879.
4. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203.
5. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
6. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012; 22: 436-445.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
8. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncol 2010; 11: 121-128.
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
10. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-13311.
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
12. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
13. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6: 201-205.
14. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant nonsmall-cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
15. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
16. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012; 22: 2109-2119.
17. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997; 277: 333-338.
18. Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012; 44: 1006-1014.
19. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-263.
20. Kawazu M, Ueno T, Kontani K, Ogita Y, Ando M, Fukumura K et al. Transforming mutations of RAC guanosine triphosphatases in human cancers. Proc Natl Acad Sci USA 2013; 110: 3029-3034.
21. Genomes Project CAbecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM et al. An integrated map of genetic variation from 1092 human genomes. Nature 2012; 491: 56-65.
22. Atlas TCG. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med 2013; 368: 2059-2074.
23. Gomez-Segui I, Makishima H, Jerez A, Yoshida K, Przychodzen B, Miyano S et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia 2013; 27: 1943-1946.
24. Shao H, Kadono-Okuda K, Finlin BS, Andres DA. Biochemical characterization of the Ras-related GTPases Rit and Rin. Arch Biochem Biophys 1999; 371: 207-219.
25. Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007; 44: 131-135.
26. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A et al. Cosmic 2005. Br J Cancer. 2006; 94: 318-322.
27. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603-607.
28. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res 2010; 16: 3670-3683.
29. Lee CH, Della NG, Chew CE, Zack DJ. Rin, a neuron-specific and calmodulinbinding small G-protein, and Rit define a novel subfamily of ras proteins. J Neurosci 1996; 16: 6784-6794.
30. Rusyn EV, Reynolds ER, Shao H, Grana TM, Chan TO, Andres DA et al. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Oncogene 2000; 19: 4685-4694.
31. Shi GX, Andres DA. Rit contributes to nerve growth factor-induced neuronal differentiation via activation of B-Raf-extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades. Mol Cell Biol 2005; 25: 830-846.
32. Shi GX, Rehmann H, Andres DA. A novel cyclic AMP-dependent Epac-Rit signaling pathway contributes to PACAP38-mediated neuronal differentiation. Mol Cell Biol 2006; 26: 9136-9147.
33. Pittman RN, Wang S, DiBenedetto AJ, Mills JC. A system for characterizing cellular and molecular events in programmed neuronal cell death. J Neurosci 1993; 13: 3669-3680.
34. Bar-Sagi D, Feramisco JR. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell 1985; 42: 841-848.
35. Cai W, Rudolph JL, Harrison SM, Jin L, Frantz AL, Harrison DA et al. An evolutionarily conserved Rit GTPase-p38 MAPK signaling pathway mediates oxidative stress resistance. Mol Biol Cell 2011; 22: 3231-3241.
36. Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Human Genet 2013; 93: 173-180.
37. Yang X, Boehm JS, Yang X, Salehi-Ashtiani K, Hao T, Shen Y et al. A public genome-scale lentiviral expression library of human ORFs. Nat Methods 2011; 8: 659-661.
38. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009; 4: 5-11.
39. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al. Highthroughput oncogene mutation profiling in human cancer. Nat Genet 2007; 39: 347-351.
40. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, Peifer M et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 2009; 119: 1727-1740.
41. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14: 4275-4283.
42. Lamprecht MR, Sabatini DM, Carpenter AE. CellProfiler: free, versatile software for automated biological image analysis. BioTechniques 2007; 42: 71-75.
43. Clark GJ, Cox AD, Graham SM, Der CJ. Biological assays for Ras transformation. Methods Enzymol 1995; 255: 395-412.